Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
APRIL trial: what clinicians have said so far
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
- NCT03287804 ↗
- Terminated
- Autolus Limited
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on APRIL yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on APRIL so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Multiple Myeloma
- Interventions
- AUTO2
- Arms
- AUTO2 · Experimental
- Enrollment
- 12
- Primary outcomes
- Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period
- Phase I - Number of Subjects With a Dose Limiting Toxicity (DLT)
- Number of Infused Patients With Best Overall Response
- Sponsor
- Autolus Limited
- Start
- May 5, 2017
- Primary completion
- Sep 5, 2019
- Results posted
- Yes
- Registry record
- NCT03287804 · updated Oct 23, 2020
Publications
linked from the registry- Lee L, Lim WC, Galas-Filipowicz D, Fung K, Taylor J, Patel D, Akbar Z, Alvarez Mediavilla E, Wawrzyniecka P, Shome D, Reijmers RM, Gregg T, Wood L, Day W, Cerec V, Ferrari M, Thomas S, Cordoba S, Onuoha S, Khokhar N, Peddareddigari V, Al-Hajj M, Cavet J, Zweegman S, Rodriguez-Justo M, Youg K, Pule M, Popat R. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. J Immunother Cancer. 2023 Jun;11(6):e006699. doi: 10.1136/jitc-2023-006699. PubMed 37399355